CA3159087A1 - Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof - Google Patents

Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Info

Publication number
CA3159087A1
CA3159087A1 CA3159087A CA3159087A CA3159087A1 CA 3159087 A1 CA3159087 A1 CA 3159087A1 CA 3159087 A CA3159087 A CA 3159087A CA 3159087 A CA3159087 A CA 3159087A CA 3159087 A1 CA3159087 A1 CA 3159087A1
Authority
CA
Canada
Prior art keywords
disorder
compound
composition
less
gabaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159087A
Other languages
English (en)
French (fr)
Inventor
Andrew D. Levin
Neil Buckley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eliem Therapeutics UK Ltd
Original Assignee
Eliem Therapeutics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eliem Therapeutics UK Ltd filed Critical Eliem Therapeutics UK Ltd
Publication of CA3159087A1 publication Critical patent/CA3159087A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3159087A 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof Pending CA3159087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907763P 2019-09-30 2019-09-30
US62/907,763 2019-09-30
PCT/US2020/052167 WO2021067089A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3159087A1 true CA3159087A1 (en) 2021-04-08

Family

ID=75338529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159087A Pending CA3159087A1 (en) 2019-09-30 2020-09-23 Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof

Country Status (9)

Country Link
EP (1) EP4135710A4 (zh)
JP (1) JP2022552788A (zh)
KR (1) KR20220103707A (zh)
CN (1) CN115087450A (zh)
BR (1) BR112022006085A2 (zh)
CA (1) CA3159087A1 (zh)
IL (1) IL291835A (zh)
MX (1) MX2022003823A (zh)
WO (1) WO2021067089A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161530A4 (en) * 2020-06-08 2024-06-26 Eliem Therapeutics (UK) Ltd METHODS FOR TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES
WO2024020953A1 (zh) * 2022-07-28 2024-02-01 湖南科益新生物医药有限公司 治疗中枢神经系统疾病的甾体化合物及其制备方法、用途和药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
PT3498725T (pt) * 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN109890392A (zh) * 2016-10-14 2019-06-14 马瑞纳斯制药公司 施用神经类固醇以实现脑电图（eeg）爆发抑制的方法
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof

Also Published As

Publication number Publication date
EP4135710A4 (en) 2023-12-06
IL291835A (en) 2022-06-01
EP4135710A1 (en) 2023-02-22
WO2021067089A1 (en) 2021-04-08
BR112022006085A2 (pt) 2023-03-14
CN115087450A (zh) 2022-09-20
JP2022552788A (ja) 2022-12-20
KR20220103707A (ko) 2022-07-22
MX2022003823A (es) 2022-08-17

Similar Documents

Publication Publication Date Title
US11571432B2 (en) Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
DE69627852T2 (de) Verbindungen, die an einer neuen stelle auf rezeptor-stimulierten kalziumkanälen wirksam sind, verwendbar zur behandlung von neurologischen krankheiten
JP2016065085A (ja) モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
EP2260022B1 (de) Substituierte cyclohexyldiamine
CA3159087A1 (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
US20100035862A1 (en) Novel aza-cyclic indole-2-carboxamides and methods of use thereof
JP2016172717A (ja) ニコチン性受容体非競合的アンタゴニスト
JP6831376B2 (ja) トリアゾール誘導体
US11958821B2 (en) Phenethylamine compounds salts, polymorphic forms and methods of use thereof
JP2019509987A (ja) Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体
JP2018531253A6 (ja) トリアゾール誘導体
JP6490187B2 (ja) 置換アザスピロ（４．５）デカン誘導体
US20220296614A1 (en) Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders
WO2012118409A2 (ru) Спироциклические никлопропановые аминокислоты - аналоги γ -аминомасляной кислоты, с ограниченной конформационной подвижностью и лекарственные средства на их основе
EP4199723A1 (en) Methods of treating fibromyalgia with neuroactive steroids
US20210323927A1 (en) Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1
CA3232914A1 (en) Lsd derivatives, synthesis & method for treatment of diseases and disorders
WO2023130117A1 (en) Deuterated organic compounds and uses thereof
WO2023130119A1 (en) Deuterated organic compounds and uses thereof
JP2020537664A (ja) （２２Ｅ）−（２４Ｒ）−２−メチレン−２２−デヒドロ−１α，２４，２５−トリヒドロキシ−１９−ノル−ビタミンＤ３の結晶化手順
JP2014532708A (ja) ニコチン性受容体非競合的モジュレーター
CN101370771A (zh) 作为钙通道阻断剂的二苯衍生物